Similar to a practicing low vision therapist, the GuideMe Book for age-related macular degeneration gathers personal information from the client, then offers guidance and resources unique to the client’s personal needs and goals. Prevent Blindness, a patient advocacy organization preserving vision and eye health for more than 115 years, continues to give the gift of [Read More]
Category: Therapies, Treatments, and Procedures
First Treatment For Geographic Atrophy Approved
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Visual Impairment in Senior Adults Apellis Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved SYFOVRE™ (pegcetacoplan injection) 15mg/0.1mL, the first and only treatment for geographic atrophy (GA) secondary to age-related [Read More]
Important Information About SYFOVRE
Do not receive SYFOVRE if you: have an infection in or around your eye have active swelling in or around your eye that may include pain and redness SYFOVRE can cause serious side effects: Eye infection (endophthalmitis) or separation of layers of the retina (retinal detachment) Call your healthcare provider right away if you have [Read More]
Susvimo implant for Wet AMD Voluntarily Recalled
BYOOVIZ™ Launches in the U.S.
Biogen Inc. and Samsung Bioepis Co., Ltd. has announced that BYOOVIZ™ (ranibizumab-nuna), a biosimilar of LUCENTIS® (ranibizumab) has been launched in the U.S. and will be commercially available on July 1, 2022. The list price will be $1,130 per injection, which is 40% lower than the current list price of LUCENTIS. The FDA approved BYOOVIZ [Read More]